United States Renal Data System.USRDS 1999 Annual data report.Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1999.
2.
Canada-USA (CANUSA) Peritoneal Dialysis Study Group.Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes.J Am Soc Nephrol1996; 7: 198–207.
3.
FriedL.F., BernardiniJ., JohnstonJ.R., PirainoB.Peritonitis influences mortality in peritoneal dialysis patients.J Am Soc Nephrol1996; 7: 2176–82.
4.
GolperT.A., BrierM.E., BunkeM., SchreiberM.J., BartlettD.K., HamiltonR.W., for the Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. Risk factors for peritonitis in long-term peritoneal dialysis.Am J Kidney Dis1996; 26: 428–36.
5.
PirainoB.A review of Staph. aureus exit-site and tunnel infections in peritoneal dialysis patients.Am J Kidney Dis1990; 16: 89–95.
6.
BernardiniJ., PirainoB., HolleyJ., JohnstonJ., LutesR.A randomized controlled trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: Mupirocin calcium ointment 2% applied to the catheter exit-site versus cyclic oral rifampin.Am J Kidney Dis1996; 27: 695–700.
7.
ThodisE., BhaskaranS., PasadakisP., BargmanJ.M., VasS.I., OreopoulosD.G.Decrease in Staphylococcus aureus exit-site infections and peritonitis in CAPD patients by local application of mupirocin ointment at the catheter exit site.Perit Dial Int1998; 18: 261–70.
8.
MillerM.A., DascalA., ProtnoyJ., MendelsonJ.Development of mupirocin resistance among methicillin resistant Staphylococcus aureus after widespread usage of nasal mupirocin ointment.Infect Control Hosp Epidemiol1996; 17: 811–13.
9.
VasS.I., ConlyJ., BargmanJ.M., OreopoulosD.G.Resistance to mupirocin: No indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients.Perit Dial Int1999; 19: 313–14.
